The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.
 
Masanao Seki
Employment - Taiho Pharmaceutical
 
Kazuhisa Minamiguchi
Employment - Taiho Pharmaceutical
 
Daisuke Kajiwara
Employment - Taiho Pharmaceutical
 
Hiroya Mizutani
Employment - Taiho Pharmaceutical
 
Shohei Yoshida
Employment - Taiho Pharmaceutical
 
Eiji Sasaki
Employment - Taiho Pharmaceutical
 
Teruhiro Utsugi
Employment - Taiho Pharmaceutical
Leadership - Taiho Pharmaceutical
 
Yoshikazu Iwasawa
Employment - Taiho Pharmaceutical
Leadership - Taiho Pharmaceutical